CN101066278A - 能量合剂的医药新用途 - Google Patents
能量合剂的医药新用途 Download PDFInfo
- Publication number
- CN101066278A CN101066278A CN 200710052253 CN200710052253A CN101066278A CN 101066278 A CN101066278 A CN 101066278A CN 200710052253 CN200710052253 CN 200710052253 CN 200710052253 A CN200710052253 A CN 200710052253A CN 101066278 A CN101066278 A CN 101066278A
- Authority
- CN
- China
- Prior art keywords
- energy mixture
- group
- energy
- mixture
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 102000004877 Insulin Human genes 0.000 abstract description 5
- 108090001061 Insulin Proteins 0.000 abstract description 5
- 229940125396 insulin Drugs 0.000 abstract description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 239000005515 coenzyme Substances 0.000 abstract description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 abstract 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000009189 diving Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229960003001 adenosine triphosphate disodium Drugs 0.000 description 2
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | n | 错误次数 | 潜伏期(S) |
正常对照组 | 10 | 0.7±0.38** | 248.6±39.03** |
模型组 | 10 | 3.8±1.10 | 138.7±12.87 |
阳性对照组 | 10 | 2.2±0.67* | 212.3±24.93* |
能量合剂小剂量组 | 10 | 2.1±0.98* | 213.6±33.24* |
能量合剂大剂量组 | 10 | 1.6±0.42** | 226.5±33.06** |
组别 | n | 错误次数 | 潜伏期(S) |
正常对照组 | 10 | 1.91±1.47** | 218.22±26.87** |
模型组 | 10 | 20.15±13.12 | 109.51±11.38 |
阳性对照组 | 10 | 8.72±5.56* | 174.63±24.02* |
能量合剂小剂量组 | 10 | 8.90±4.28* | 172.60±22.36* |
能量合剂大剂量组 | 10 | 6.72±3.46** | 190.37±25.69** |
组别 | n | 脑重(克) |
正常对照组 | 10 | 1.47±0.09* |
模型组 | 10 | 1.08±0.06 |
阳性对照组 | 10 | 1.44±0.07* |
能量合剂小剂量组 | 10 | 1.45±0.08* |
能量合剂大剂量组 | 10 | 1.49±0.09** |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710052253A CN101066278B (zh) | 2007-05-25 | 2007-05-25 | 能量合剂的医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710052253A CN101066278B (zh) | 2007-05-25 | 2007-05-25 | 能量合剂的医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101066278A true CN101066278A (zh) | 2007-11-07 |
CN101066278B CN101066278B (zh) | 2010-05-19 |
Family
ID=38879057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710052253A Expired - Fee Related CN101066278B (zh) | 2007-05-25 | 2007-05-25 | 能量合剂的医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101066278B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698253A (zh) * | 2012-06-08 | 2012-10-03 | 夏智红 | 一种三磷酸腺苷辅酶胰岛素组合物 |
CN103520190A (zh) * | 2013-09-29 | 2014-01-22 | 陈铭 | 防治老年神经退行性疾病的高能物质及其医药用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
CN1679924A (zh) * | 2005-02-03 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | 复方胰岛素能量合剂制剂及其应用 |
-
2007
- 2007-05-25 CN CN200710052253A patent/CN101066278B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698253A (zh) * | 2012-06-08 | 2012-10-03 | 夏智红 | 一种三磷酸腺苷辅酶胰岛素组合物 |
CN102698253B (zh) * | 2012-06-08 | 2013-05-01 | 夏智红 | 一种三磷酸腺苷辅酶胰岛素组合物 |
CN103520190A (zh) * | 2013-09-29 | 2014-01-22 | 陈铭 | 防治老年神经退行性疾病的高能物质及其医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101066278B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1224383C (zh) | 一类新型降低血糖化合物 | |
CN114209739A (zh) | 一种白头翁提取物在制备治疗抗抑郁药物上的应用 | |
CN101066278B (zh) | 能量合剂的医药用途 | |
CN107468683A (zh) | 土木香内酯及其衍生物在预防和治疗脂肪肝损伤中的用途 | |
CN101062041A (zh) | 葫芦素新的医药用途 | |
CN109419787B (zh) | 一种松香烷型二萜类化合物的用途 | |
CN102178697B (zh) | 一种复方水蛭胶囊及其制备方法 | |
CN104771518B (zh) | 一种抗炎、治疗或辅助治疗猪发热病的药物组合物及其制备方法 | |
CN110092806B (zh) | 附子中具有镇痛作用的c19二萜生物碱糖苷及其用途 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN106265713B (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
CN100525783C (zh) | 使君子或其提取物在制备促进排铅作用中药制剂中的应用 | |
CN1814194A (zh) | 一种治疗小儿感冒的中西药组合物及其应用 | |
CN100579519C (zh) | 百秋李醇在制备防治老年性痴呆症的药物中的用途 | |
CN110327345B (zh) | 一种防治缺血性脑中风的磷酸二酯酶9a抑制剂的用途 | |
CN109674859A (zh) | 酸枣仁生物碱与黄酮配伍防治抑郁失眠疾病 | |
EP0500901B1 (en) | Pharmaceutical compositions for use in treating parkinson's disease | |
CN108421031A (zh) | 藻蓝蛋白在制备防治帕金森病药物中的应用 | |
CN102727506A (zh) | 天麻派立辛提取物在制备脑保护药物中的应用 | |
CN1682715A (zh) | 一种抗缺氧药物组合物 | |
CN106831386A (zh) | 新型蕨素类化合物在治疗糖尿病的应用 | |
CN107213154B (zh) | 一种用于促进手术后麻醉觉醒和神经损伤保护的护理药物组合物及其用途 | |
CN1943573A (zh) | 维生素c和精氨酸组合物在抗缺氧药物和保健品中的应用 | |
CN105362996A (zh) | 一种治疗疱疹病毒的中药提取物及其制备方法与应用 | |
CN101919854B (zh) | 小唐松草醛碱作为制备治疗心律失常药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine use of energy mixture Effective date of registration: 20110201 Granted publication date: 20100519 Pledgee: Bank of Communications Ltd Wuhan East Lake New Technology Development Zone sub branch Pledgor: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Registration number: 2011990000041 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180628 Granted publication date: 20100519 Pledgee: Bank of Communications Ltd Wuhan East Lake New Technology Development Zone sub branch Pledgor: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Registration number: 2011990000041 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20190525 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: WUHAN TONGYUAN PHARMACEUTICAL Co.,Ltd. Document name: Notification of Termination of Patent Right |